纤维化分期而非NASH可预测经活检证实的NAFLD患者的死亡率和严重肝病发展时间
这项回顾性队列研究纳入646例经活检证实的NAFLD患者,按年龄、性别和市镇与10倍对照匹配,随访平均20年。结果显示严重肝病风险随纤维化分期增加而升高(F0风险比1.9至F4风险比104.9),而合并NASH并未显著改变这些估计值;总体死亡率结果类似。
要点
- 纤维化分期而非NASH是预测NAFLD患者死亡和严重肝病风险的关键因素。
- 严重肝病风险随纤维化分期递增,F0风险比1.9,F4风险比104.9。
- 合并NASH未显著改变纤维化分期与不良结局之间的关联。
核心结论
- 在这项迄今最大规模的经活检证实的NAFLD研究中,NASH的存在并未增加肝脏特异性疾病或总体死亡的风险。
- 根据纤维化分期了解严重肝病的发展时间可用于个体患者咨询和公共卫生决策。
研究设计与样本
- 回顾性队列研究,纳入646例经活检证实的NAFLD患者,每例按年龄、性别和市镇与10名对照匹配。
- 使用人群登记资料评估死亡和严重肝病(肝硬化、肝失代偿/肝衰竭或肝细胞癌)结局。
- 采用Cox回归模型(校正年龄、性别和2型糖尿病)检验纤维化分期的长期风险,似然比检验评估加入NASH是否提高预测能力,Laplace回归估计不同纤维化分期发展至严重肝病的时间。
主要发现
- 随访平均20年(范围0-40年),相当于139,163人年,12%的NAFLD患者和2.2%的对照发生严重肝病(p<0.001)。
- 与对照相比,严重肝病风险随纤维化分期增加(风险比从F0的1.9至F4的104.9)。
- 校正NASH存在后这些估计值无显著变化(所有纤维化分期的似然比检验>0.05)。
- 总体死亡率结果类似。
- 发展至严重肝病时间第10百分位的95%置信区间下限:F0-1为22-26年,F2为9.3年,F3为2.3年,F4为0.9年(至肝失代偿)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) is very common in the general population, but identifying patients with increased risk of mortality and liver-specific morbidity remains a challenge. Non-alcoholic steatohepatitis (NASH) is thought to enhance this risk; therefore, resolution of NASH is a major endpoint in current pharmacologic studies. Herein, we aim to investigate the long-term prognosis of a large cohort of NAFLD patients, and to study the specific effect of NASH and fibrosis stage on prognosis. METHODS: We conducted a retrospective cohort study of 646 biopsy-proven NAFLD patients. Each case was matched for age, sex and municipality to ten controls. Outcomes on mortality and severe liver disease, defined as cirrhosis, liver decompensation/failure or hepatocellular carcinoma, were evaluated using population-based registers. Cox regression models adjusted for age, sex and type 2 diabetes were used to examine the long-term risk according to fibrosis stage. Likelihood ratio tests were used to assess whether adding NASH to these models increased the predictive capacity. Laplace regression was used to estimate the time to severe liver disease according to stage of fibrosis. RESULTS: During a follow-up of mean 20years (range 0-40) equivalent to 139,163 person-years, 12% of NAFLD patients and 2.2% of controls developed severe liver disease (p<0.001). Compared to controls, the risk of severe liver disease increased per stage of fibrosis (hazard ratio ranging from 1.9 in F0 to 104.9 in F4). Accounting for the presence of NASH did not change these estimates significantly (likelihood ratio test >0.05 for all stages of fibrosis). Similar results were seen for overall mortality. The lower end of the 95% confidence interval for the 10th percentile of time to development of severe liver disease was 22-26years in F0-1, 9.3years in F2, 2.3years in F3, and 0.9years to liver decompensation in F4. CONCLUSIONS: In this, the largest ever study of biopsy-proven NAFLD, the presence of NASH did not increase the risk of liver-specific morbidity or overall mortality. Knowledge of time to development of severe liver disease according to fibrosis stage can be used in individual patient counselling and for public health decisions. LAY SUMMARY: Non-alcoholic fatty liver disease (NAFLD) is very common in the general population, but reaching an accurate prognosis remains challenging. We investigate the long-term prognosis of a large cohort of NAFLD patients. In this, the largest ever study of biopsy-proven NAFLD, the presence of NASH did not increase the risk of liver-specific morbidity or overall mortality. Knowledge of time to development of severe liver disease according to fibrosis stage can be used in individual patient counselling and for public health decisions.
引用
- Hagström H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017. PMID: 28803953. doi:10.1016/j.jhep.2017.07.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。